Table 2.
Patient characteristics for all patients who received LMWH and UFH
| LMWH (n = 180) | UFH (n = 776) | P-value | |
|---|---|---|---|
| Age, years, mean (SD) | 50.4 (21.4) | 55.8 (22.5) | 0.004 |
| Platelets, mean (SD) | 103.8 (110) | 84.9 (60.6) | 0.002 |
| Sex | |||
| Males (%) | 69 (38.3%) | 392 (50.5%) | 0.003 |
| Females (%) | 111 (61.7%) | 384 (49.5%) | 0.003 |
| HIT testing results | |||
| Negative, n (%) | 175 (97.2%) | 725 (93.4%) | 0.051 |
| Positive, n (%) | 5 (2.8%) | 51 (6.6%) | 0.051 |
| Heparin Route | |||
| Intravenous, n (%) | 0 (0.0%) | 302 (38.9%) | <0.001 |
| Subcutaneous, n (%) | 179 (99.4%) | 364 (46.9%) | <0.001 |
| Both, n (%) | 1 (0.6%) | 110 (14.2%) | <0.001 |
LMWH: Low molecular weight heparin; UFH: Unfractionated heparin; HIT: Heparin induced thrombocytopenia. We compared the differences between the 2 groups (UFH and LMWH) using chi squared tests for categorical variables (sex, HIT testing results, Heparin Route) and using T-test for continuous variables (age and platelets).